SynthesisApplied health economics and health policy2018
The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review.
Synthesis in Applied health economics and health policy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Population-Wide Screening for Chronic Kidney Disease : A Cost-Effectiveness Analysis.Annals of internal medicine · 2023Trial
- Article
- A nationwide register study on medicines exiting the reimbursement system in 2010-2022.BMC health services research · 2026Article
- Availability and Costs of Allergic Rhinitis Treatments Across the World: A Survey of ARIA Experts.Allergy · 2026Article
- Sales Erosion of Originator Drugs Following Generic Entry: Quantitative Analysis and Predictive Modeling.Therapeutic innovation & regulatory science · 2026Article
- Article
- Treating hypertension with single pill combinations: a simple strategy to save costs for the patients and payers.Journal of hypertension · 2025Article
- Effects of Generic Entry on Market Shares and Prices of Originator Drugs: Evidence from Chinese Pharmaceutical Market.PharmacoEconomics - open · 2025Article
- Quantifying the Human Mortality Costs of Patent-based Intellectual Property: How Many Premature Deaths are due to Patents?Health care analysis : HCA : journal of health philosophy and policy · 2025Article
- Defining a Framework for Sustainable Global Biosimilars Markets Using Findings from a Targeted Literature Review.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Cost-Effectiveness Analysis of Contemporary Advanced Prostate Cancer Treatment Sequences.Current oncology (Toronto, Ont.) · 2025Article
- Compliance With Parathyroid Hormone Analog Medications at a Single Osteoporosis Treatment Center.Cureus · 2025Article
- Article
- International comparison of generic competition, prices, and usage trends: South Korea and G20 countries.Frontiers in public health · 2025Article
- Patent landscape of nanotechnology - based nucleic acid delivery systems for breast cancer therapies.Frontiers in oncology · 2025Article
- Drug Prices After Patent Expirations in High-Income Countries and Implications for Cost-Effectiveness Analyses.JAMA health forum · 2024Article
- Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices.Forum for health economics & policy · 2024Article
- Impact of Incorporating Future Mandatory Price Reductions with Generic Drug Entry on the Cost-Effectiveness of New Drugs: A Policy Simulation Study of Dupilumab in Atopic Dermatitis Treatment.Healthcare (Basel, Switzerland) · 2024Article
- Cost-effectiveness of home-based screening of the general population for albuminuria to prevent progression of cardiovascular and kidney disease.EClinicalMedicine · 2024Article
- Cost-effectiveness of COVID-19 vaccination in Latin America and the Caribbean: an analysis in Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, and Peru.Cost effectiveness and resource allocation : C/E · 2023Article
Corrections and comments
- Commented on by
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to evaluate the impact of patent expiry on drug prices by means of a systematic literature review.
methodsA systematic literature search was performed in PubMed to identify all published literature on the impact of patent expiration on drug prices. Additional literature was identified using a less distinct syntax in Google Scholar and EconLit. Data extraction followed a standardized assessment form containing the domains study type, study aim, reported outcomes, number of drugs and drug classes assessed, and originators or generics assessed.
resultsThe 16 identified studies that assessed impact of patent expiry on drug prices showed that price developments after patent expiration varied between countries. The included studies assessed price developments for the USA, Canada, Australia, the UK, the Netherlands, Germany and France, Spain, Italy, Norway, Sweden and Denmark. The number of drugs included within different studies ranged between 1 and 219. The identified studies indicated that drug prices decreased significantly after patent expiry with drug price ratios ranging from 6.6 to 66% 1-5 years after patent expiry.
conclusionDrug prices decrease significantly after patent expiry. The extent of this price reduction varied greatly between products and countries. For this reason, country-specific analyses on price developments after patent expiry should be used when these are considered in decision making. Future research should be dedicated to gathering more country-specific data to reduce the uncertainty with regard to price developments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.